son's disease (PD) (MIM 168600), the second most common neurodegenerative disorder after Alzheimer's disease. While most patients with PD develop symptoms after the age of 50, a small subset of patients (5%-10%) manifest early-onset PD (EOPD) [1] [2] [3] and are more likely to harbor recognized genetic risk factors. 1, 2, 4 Levodopa-responsive Parkinsonism presenting in infancy or childhood is extraordinarily rare and may occur as a comorbidity to other diseases or genetic conditions. 5 
| MATERIALS AND METHODS

| Clinical data and samples
The patient, following informed and written consent, under the pro- 
| Genetic analysis
High density whole genome SNP array methods were done as described in Reference 10.
Whole exome sequencing of both parents and the patient was performed at NIH Intramural Sequencing Center (NISC). SureSelectV5
(Agilent Technologies) was used for exome capture and subsequent sequencing was done on a HiSeq2000 instrument (Illumina Inc.). Sample library preparation, sequencing, and analysis were performed using the standard NISC pipeline 11 and Axeq Technologies (Seoul, South Korea). The analysis of whole exome sequencing data is described below.
Whole-exome sequence analysis was performed on genomic DNA that was isolated from the patient and his unaffected mother and father. The quality of whole exome data is shown in Table S1 (Supporting information).
The sequencing reads then were filtered for quality, and aligned to human reference genome NCBI build 37 (hg19) using in-house 16 and Exomiser. 17 The quality of alignment and genotype call of variants were checked using the Integrative 
| Analysis of dermal fibroblasts
A culture of dermal fibroblasts from the patient was established as previously described. 18 Control fibroblasts were purchased from Cor- 3 | RESULTS
| Clinical description
The patient was the first and only child born to non-consanguineous parents of European descent with no relevant family history. He was born at 37 weeks of gestation as a product of in vitro fertilization that was necessary because of tubal factor infertility. Due to premature labor that started at 23 weeks gestation and maternal bleeding related to placenta previa, he was delivered via cesarean section.
Apgar scores were 9 and 9 out of 10 (at 1 and 5 minutes), with birth weight of 3302 g, length of 50.8 cm, and unknown occipital frontal circumference or OFC. Following delivery, he was noted to have pneumothorax and received a chest tube and was monitored on a ventilator for 4 days. He also developed a mild form of jaundice, but did not require phototherapy and was discharged at 5 days.
Early development was normal until the age of 1 when he was first noted to have left leg tremor while learning to stand. At 
| Clinical data and samples
The patient, following informed and written consent, was admitted in the NIH Clinical Center under the protocol 76-HG-0238, "Diagnosis 
| Genetic analysis
Pathogenic SNPs, small insertions/deletions, and copy number and structural variants in the PD-associated genes PINK1, PRKN, PARK7, and SCNA were ruled out by whole exome sequencing and whole genome single nucleotide polymorphism (SNP) array analysis. Top candidate variants were identified in several genes including KDM5C, LRCH2, FRY, CUL4A, SETD6, and WARS2 (Table S2 in Appendix S1).
Specifically, the patient was compound heterozygous for 2 variants in WARS2 (NM_015836.3): a missense variant c.37T>G (p.Trp13Gly)
that was inherited from his mother and a missense variant c.683C>G
(p.Ser228Trp) that was inherited from his father. The p.Trp13Gly variant is present in the ExAC database with an allelic frequency of 0.003383 and is not predicted to be extremely deleterious (Table 1) .
However, its location in the mitochondrial localization signal of the protein gives it functional relevance. In a recent report by Musante et al, the p.Trp13Gly variant was found to significantly reduce the level of WARS2 protein in the mitochondrial fraction, indicating that this mutation leads to mislocalization. 9 The p.Ser228Trp variant is not present in the ExAC database. Using wInterVar, p.Trp13Gly had an adjusted score of likely pathogenic (PS1, PM3, BP4) and p.Ser228Trp
had an adjusted score of likely pathogenic (PS3, PM2, PP3).
| Analysis of dermal fibroblasts
Western blot analysis of patient fibroblasts revealed a marked decrease in WARS2 steady-state protein levels relative to controls, demonstrating a functional consequence of the identified WARS2 variants ( Figure 2C ). The steady state levels of OXPHOS subunits NDUFB8 (CI), UQCRC2 (CIII), COXI (CIV) and ATP6 (CV) were relatively unaffected in the patient as compared to controls ( Figure 2C ), using SDHA (CII) as a loading control since CII is entirely nuclear-encoded.
| Muscle biopsy analysis
A quadriceps muscle biopsy had non-specific changes including mild variation in fiber size with rare atrophic fiber, and normal COX and 
| DISCUSSION
Numerous publications have documented significant phenotypic variability caused by defects in mtARS genes. 6, 7 Patients harboring biallelic mutation in AARS2, for example, may present with intrauterine or perinatal cardiomyopathy, 20 adolescent onset ovario leukodystrophy 21 or late-onset neurodegeneration in patients with hereditary diffuse leukoencephalopathy with spheroids (HDLS). 22 The explanation for the broad range of manifestations is unclear.
The latest mtARS to be linked to a disease is WARS2, based upon 2 independent case reports. Musante et al 9 or different methodologies. In general, it is not uncommon for mtARS defects to have no effect on RC subunit expression in patient fibroblasts. 23 Interestingly, the mtDNA content of the muscle is still lower than age-matched control; this, together with the finding of increased mitochondrial CoQ10 content may suggest some compensation for the mtDNA depletion.
WES and whole genome SNP array data analysis for known variants and copy number variations associated with PD did not yield to the need for DBS at age 10 to achieve control of motor complications.
In conclusion, we expand the phenotypic spectrum of disorders caused by biallelic mutations in WARS2 gene to include infantileonset, Levodopa-responsive Parkinsonism and implicate WARS2 dysfunction as a potential driver of mitochondrial dysfunction leading to nigrostriatal degeneration and Parkinsonism.
